Citation: | WANG Feng. Influence of linagliptin on the blood glucose change in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2014, (13): 99-101. DOI: 10.7619/jcmp.201413033 |
中国老年学学会老年医学会老年内分泌代谢专业委员会, 老年糖尿病诊疗措施专家共识编写组. 老年糖尿病诊疗措施专家共识(2013 年版) [J]. 中华内科杂志, 2014(3):243.
|
Rosenstock J, Dal ey G, Maasi-benedetti G, et a1. Re-duced hypoglycemia risk with insulin glargine:a meta-anal-ysis comparing insulin glargine with human NPH insulin in type 2 diabetes [J]. DIABETES CARE, 2005(4):950.
|
Amori R, Lau J, Pittas A. Efficacy and safety of incertin therapy in type 2 diabetes [J]. JAMA:the Journal of the American Medical Association, 2007(2):194.
|
Holman R R, Thome K I, Farmer A J. Addition of biphasic, prandialor basal insulin to oral therapy in type 2 dia-betes [J]. N Ensl J Med, 2007, (17):1716.
|
Park C Y, Kang J G, Chon S. Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrol ed Patients with Type 2 Diabetes [J]. PLoS One, 2014(3):e87799.
|
Nauck M A. Incretin-based therapies for type 2 diabetes mel itus:properties, functions, and clinical implications [J]. American Journal of Medicine, 2011, (1 Suppl):S3.
|
Forst T, Uhlig-Laske B, Ring A. The oral DP-4inhibitor linagliptin significantly lowers HbA1c after 4 weeks oftreatment in patients with type 2 diabetes mel itus [J]. Di-abetesObes Metab, 2011(6):542.
|
Graefe-Mody U, Rose P, Retlich S. Pharmacokinet-ics of linagliptin in subjects with hepatic impairment [J]. British Journal of Clinical Pharmacology(England), 2012, (10):1365.
|
Schernthaner G, Barnett A H, Emser A. Safety and tolerability of linagliptin:a pooled analysis of data from ran-domized control ed trials in 3572 patients with type 2diabetes mel itus [J]. Diabetes Obesity & Metabolism, 2012(5):470.
|
del P S, Baenett A, Huisman H. Effect of linagliptin monotherapy on glycaemic control and markers of β-cellfunction in patients with inadequately control ed type 2diabetes:a randomized control ed trial [J]. Diabetes Obesity & Metabolism, 2011(3):258.
|
Taskinen M R, Rosenstock J, Tamminen I. Safety and efficacy of linagliptin as add-on therapy to metformin inpa-tients with type 2 diabetes:a randomized, double-blind, placebo-control ed study [J]. Diabetes Obesity & Metabolism, 2011(1):65.
|
Gomis R, Espadero R M, Jones R. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately control ed type 2diabetes:a ran-domized, double-blind, placebo-control ed study [J]. Dia-betes Obes Metab, 2011(7):653.
|